The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics

DOI Web Site Web Site 被引用文献1件
  • David C. Klonoff
    Diabetes Research Institute; Mills-Peninsula Health Services, San Mateo, CA, USA

書誌事項

公開日
2019-03-12
権利情報
  • http://journals.sagepub.com/page/policies/text-and-data-mining-license
DOI
  • 10.1177/1932296819832661
公開者
SAGE Publications

この論文をさがす

説明

<jats:p> FDA has launched a Real World Evidence (RWE) Program for using real-world evidence (RWE) to help support new indications for already approved drugs or biologics and postapproval studies. The plan also includes stakeholder engagement efforts, demonstration projects, leadership activities, and development of guidance documents to assist developers interested in using real-world data (RWD) to develop RWE to support FDA regulatory decisions. This plan was mandated by the Cures Act passed in 2016. Over the 24-month period from passage of the law until FDA officially announced their program, FDA has gone to considerable efforts to educate the public about the benefits of RWE and encourage researchers to consider situations where RWE trials can generate useful information. Through a variety of stakeholder engagement projects, including publication of articles in medical journals, participation in public meetings, and development of initiatives, FDA has put more effort into preparing the medical community for its new emphasis on RWE than any other new policy that I can recall. </jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ